Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Indiana University
With
Genentech, Inc.
To determine the feasibility and toxicity of neoadjuvant hypofractioned radiotherapy concurrently with weekly gemcitabine and an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva) in the treatment of patients with resectable pancreatic cancer.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
pathologically confirmed adenocarcinoma of the pancreas
resectable disease
tumor \</= 6cm diameter
ECOG performance 0-1
Organ system fxn: granulocytes (\>/=1800/uL); plt ct \>/=100K; bili\</=2mg; liver enzymes \<2.5ULN; crt \</=1.5;
Normal CXR
Negative pregnancy test
You may not be if
metastatic disease or peritoneal seeding based on cross-sectional imaging
previous irradiation to the planned field
prior chemotherapy or immunotherapy
active infection
active PUD
Clareo Health | Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer
